Who Owns BDRX?

Biodexa Pharmaceuticals Plc — Institutional Ownership & 13F Holdings

$3.33

+0.03 (+0.91%)

Market Cap

$797K

Shares Outstanding

16,776

Institutional Holders

6

Total Inst. Value

$1.5M

% of Float Held

QoQ Holder Change

Institutional data as of Q1 2025

New Positions

2

Closed Positions

1

Increased

2

Decreased

0

Institutional Ownership Trend

Top 10 Institutional Holders(Q1 2025)

#FundValueShares
1GAMMA Investing LLCNew$1.4M1,882
2UBS Group AG$25K18,832
3RHUMBLINE ADVISERS$414315
4SBI Securities Co., Ltd.$11
5CONTRAVISORY INVESTMENT MANAGEMENT, INC.$040
6MORGAN STANLEYNew$0700

Biggest Buyers & Sellers This Quarter

Top Buyers

FundShares AddedValue
GAMMA Investing LLCNew+2K$1.4M
UBS Group AG+12K$25K
RHUMBLINE ADVISERS+161$414
MORGAN STANLEYNew+700$0

Top Sellers

FundShares RemovedValue

Related Stocks

Frequently Asked Questions

How many institutional investors hold BDRX?

As of Q1 2025, 6 institutional investors report holding BDRX (Biodexa Pharmaceuticals Plc) in their 13F filings.

Which hedge fund owns the most BDRX?

The largest institutional holder of BDRX is GAMMA Investing LLC with $1.4M in shares.

Are institutions buying or selling BDRX?

This quarter, 2 institutions opened new positions in BDRX and 1 closed their positions.

What is 13F institutional ownership?

SEC Form 13F is a quarterly report filed by institutional investment managers with over $100M in qualifying assets. It discloses their US equity holdings, providing transparency into what the largest investors are buying and selling.

How often is institutional ownership data updated?

13F filings are due 45 days after each calendar quarter end (May 15, Aug 14, Nov 14, Feb 14). Data is updated on HedgeTrace as new filings are processed.